[{"orgOrder":0,"company":"KIMBERLY CLARK HEALTH CARE","sponsor":"KIMBERLY CLARK HEALTH CARE","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Estradiol","moa":"estrogens","graph1":"Urology","graph2":"Phase IV","graph3":"KIMBERLY CLARK HEALTH CARE","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Cream","sponsorNew":"KIMBERLY CLARK HEALTH CARE \/ KIMBERLY CLARK HEALTH CARE","highestDevelopmentStatusID":"11","companyTruncated":"KIMBERLY CLARK HEALTH CARE \/ KIMBERLY CLARK HEALTH CARE"},{"orgOrder":0,"company":"KIMBERLY CLARK HEALTH CARE","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sumatriptan","moa":"Serotonin 1b (5-HT1b) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"KIMBERLY CLARK HEALTH CARE","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KIMBERLY CLARK HEALTH CARE \/ KIMBERLY CLARK HEALTH CARE","highestDevelopmentStatusID":"6","companyTruncated":"KIMBERLY CLARK HEALTH CARE \/ KIMBERLY CLARK HEALTH CARE"},{"orgOrder":0,"company":"KIMBERLY CLARK HEALTH CARE","sponsor":"London Health Sciences Centre Research Institute (Lawson) | Western University, Canada | Integrated Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Probiotic","year":"2014","type":"Inapplicable","leadProduct":"Lactobacillus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KIMBERLY CLARK HEALTH CARE","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KIMBERLY CLARK HEALTH CARE \/ London Health Sciences Centre Research Institute (Lawson) | Western University, Canada | Integrated Research","highestDevelopmentStatusID":"6","companyTruncated":"KIMBERLY CLARK HEALTH CARE \/ London Health Sciences Centre Research Institute (Lawson) | Western University, Canada | Integrated Research"}]

Find Clinical Drug Pipeline Developments & Deals by KIMBERLY CLARK HEALTH CARE

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Sumatriptan Succinate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Migraine Disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 26, 2017

                          Lead Product(s) : Sumatriptan

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Recipient : Sorrento Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Estrogen is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Urinary Bladder, Overactive.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          July 18, 2016

                          Lead Product(s) : Estradiol

                          Therapeutic Area : Urology

                          Highest Development Status : Phase IV

                          Recipient : Loyola University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Lactobacillus

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase I

                          Sponsor : London Health Sciences Centre Research Institute (Lawson) | Western University, Canada | Integrated Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Lactobacillus is a Probiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Vaginosis, Bacterial.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          May 15, 2014

                          Lead Product(s) : Lactobacillus

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : London Health Sciences Centre Research Institute (Lawson) | Western University, Canada | Integrated Research

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank